HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV)

HC Wainwright restated their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a research note published on Tuesday morning,Benzinga reports. The brokerage currently has a $8.00 target price on the stock.

Separately, Ascendiant Capital Markets reduced their target price on shares of Plus Therapeutics from $21.00 to $20.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

Plus Therapeutics Trading Up 1.6 %

Shares of Plus Therapeutics stock opened at $1.28 on Tuesday. The company has a market capitalization of $7.55 million, a P/E ratio of -0.51 and a beta of 0.69. The stock has a fifty day simple moving average of $1.35 and a 200 day simple moving average of $1.61. Plus Therapeutics has a 12-month low of $1.12 and a 12-month high of $2.67.

Hedge Funds Weigh In On Plus Therapeutics

A hedge fund recently bought a new stake in Plus Therapeutics stock. AIGH Capital Management LLC acquired a new stake in Plus Therapeutics, Inc. (NASDAQ:PSTV) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned 9.98% of Plus Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.